- Market Capitalization, $K 158,972,560
- Shares Outstanding, K 2,354,800
- Annual Sales, $ 18,291 M
- Annual Income, $ 5,839 M
- 60-Month Beta 0.44
- Price/Sales 8.64
- Price/Cash Flow 23.77
- Price/Book 16.65
|Period||Period Low||Period High||Performance|
| || |
+3.62 (+5.67%)since 10/30/20
| || |
+1.62 (+2.46%)since 09/01/20
| || |
+11.36 (+20.23%)since 11/29/19
A consciously conceived and designed business intelligence report titled Global by Manufacturers, Type, and Application, Forecast to 2029 by discloses a succinct analysis of the regional spectrum,...
AstraZeneca (AZN) Forxiga is approved in Japan for chronic heart failure (HF) in patients who are receiving standard of care.
Let's see if Novo Nordisk A/S (NVO) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Biotech Showcase(TM) Digital is the investor conference that drives the future of biotech innovation, digital medicine, and international collaboration. In its 13th year, the conference will be a virtual...
Novo Nordisk's (NVO) semaglutide 2.0 mg demonstrates superior reduction in HbA1c versus once-weekly semaglutide 1.0 mg in people with type II diabetes.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Emisphere Technologies, Inc. (OTC: EMIS) to Novo...
Novo Nordisk Thailand, an affiliate of the global healthcare company with more than 90 years of innovation and leadership in diabetes care, has been recognized as one of the best companies to work in Thailand...
Bagsvaerd, Denmark, 17 November 2020 - Novo Nordisk today announced headline results from the SUSTAIN FORTE trial, a phase 3b 40-week, efficacy and safety trial with once-weekly semaglutide 2.0 mg vs once-weekly...
Gilead (GILD) and Novo Nordisk present favorable outcomes from a mid-stage study in NASH patients.
- Company to receive upfront payment of EUR5 million replacing a later stage regulatory approval milestone of U.S.$5 million